Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis.
Iago Pinal-FernandezAngela QuintanaJose Cesar MilisendaMaria Casal-DominguezSandra Muñoz-BracerasAssia DerfoulJiram Torres-RuizKatherine PakStefania Dell'OrsoFaiza NazGustavo Gutierrez-CruzMargherita MiloneShahar ShellyYaiza Duque-JaimezEster Tobias-BarajaAna Matas-GarciaGloria GarrabouJoan PadrosaJavier RosErnesto Trallero-AraguásBrian WalittLisa Christopher-StineThomas E LloydChen ZhaoShannon SwiftArun RajanJosep Maria Grau-JunyentAlbert Selva O'CallaghanTeerin LiewluckAndrew Lee MammenPublished in: Annals of the rheumatic diseases (2023)
We identified three distinct types of ICI-myositis based on transcriptomic analyses. The IL6 pathway was overexpressed in all groups, the type I interferon pathway activation was specific for ICI-DM, the type 2 IFN pathway was overexpressed in both ICI-DM and ICI-MYO1 and only ICI-MYO1 patients developed myocarditis.
Keyphrases
- single cell
- end stage renal disease
- dendritic cells
- newly diagnosed
- ejection fraction
- chronic kidney disease
- interstitial lung disease
- immune response
- peritoneal dialysis
- prognostic factors
- high glucose
- type diabetes
- peripheral blood
- oxidative stress
- adipose tissue
- patient reported outcomes
- rheumatoid arthritis
- myasthenia gravis
- insulin resistance
- skeletal muscle
- patient reported
- idiopathic pulmonary fibrosis